DOI: 10.1007/s00259-017-3886-yPages: 1-1

Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

1. Centre for Cancer Imaging, Peter MacCallum Cancer Centre

2. Division of Cancer Medicine, Neuroendocrine Tumour Unit, Peter MacCallum Cancer Centre

3. Singapore General Hospital, Department of Nuclear Medicine and PET

Correspondence to:
Rodney J. Hicks
Email: Rod.Hicks@petermac.org

Close

Abstract

On page 4 of the original version of this article, the text “Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment” needs to be corrected.

This article is freely available, click here to access the full text/PDF

  • Online: Nov 20, 2017

Article Tools

eanm
EJNMMI Ad